Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(176 sites)

United States

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Banner University Medical Center - Tucson, Tucson, Arizona

University of Arizona Cancer Center-North Campus, Tucson, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California